Blur Unblurred - A Mini Tutorial

Optical blur from defocus is quite frequently considered as equivalent to low-pass filtering. Yet that belief, although not entirely wrong, is inaccurate. Here, we wish to disentangle the concepts of dioptric blur, caused by myopia or mis-accommodation, from blur due to low-pass filtering when convolving with a Gaussian kernel. Perhaps surprisinglyif well known in optometrythe representation of a blur kernel (or point-spread function) for dioptric blur is, to a good approximation and disregarding diffraction, simply a cylinder. Its projection onto the retina is classically referred to as a blur circle, the diameter of which can easily be deduced from a light-ray model. We further give the derivation of the relationship between the blur-disk's diameter and the extent of blur in diopters, as well as the diameter's relation to the near or far point, and finally its relationship to visual acuity

Two-loop amplitudes for t t ¯ H production: the quark-initiated N f -part

We present numerical results for the two-loop virtual amplitude entering the NNLO corrections to Higgs boson production in association with a top quark pair at the LHC, focusing, as a proof of concept of our method, on the part of the quark-initiated channel containing loops of massless or massive quarks. Results for the UV renormalised and IR subtracted two-loop amplitude for each colour structure are given at selected phase-space points and visualised in terms of surfaces as a function of two-dimensional slices of the full phase space

VEP estimation of visual acuity: a systematic review

PURPOSE:Visual evoked potentials (VEPs) can be used to measure visual resolution via a spatial frequency (SF) limit as an objective estimate of visual acuity. The aim of this systematic review is to collate descriptions of the VEP SF limit in humans, healthy and disordered, and to assess how accurately and precisely VEP SF limits reflect visual acuity. METHODS:The protocol methodology followed the PRISMA statement. Multiple databases were searched using "VEP" and "acuity" and associated terms, plus hand search: titles, abstracts or full text were reviewed for eligibility. Data extracted included VEP SF limits, stimulus protocols, VEP recording and analysis techniques and correspondence with behavioural acuity for normally sighted healthy adults, typically developing infants and children, healthy adults with artificially degraded vision and patients with ophthalmic or neurological conditions. RESULTS:A total of 155 studies are included. Commonly used stimulus, recording and analysis techniques are summarised. Average healthy adult VEP SF limits vary from 15 to 40 cpd, depend on stimulus, recording and analysis techniques and are often, but not always, poorer than behavioural acuity measured either psychophysically with an identical stimulus or with a clinical acuity test. The difference between VEP SF limit and behavioural acuity is variable and strongly dependent on the VEP stimulus and choice of acuity test. VEP SF limits mature rapidly, from 1.5 to 9 cpd by the end of the first month of life to 12-20 cpd by 8-12 months, with slower improvement to 20-40 cpd by 3-5 years. VEP SF limits are much better than behavioural thresholds in the youngest, typically developing infants. This difference lessens with age and reaches equivalence between 1 and 2 years; from around 3-5 years, behavioural acuity is better than the VEP SF limit, as for adults. Healthy, artificially blurred adults had slightly better behavioural acuity than VEP SF limits across a wide range of acuities, while adults with heterogeneous ophthalmic or neurological pathologies causing reduced acuity showed a much wider and less consistent relationship. For refractive error, ocular media opacity or pathology primarily affecting the retina, VEP SF limits and behavioural acuity had a fairly consistent relationship across a wide range of acuity. This relationship was much less consistent or close for primarily macular, optic nerve or neurological conditions such as amblyopia. VEP SF limits were almost always normal in patients with non-organic visual acuity loss. CONCLUSIONS:The VEP SF limit has great utility as an objective acuity estimator, especially in pre-verbal children or patients of any age with motor or learning impairments which prevent reliable measurement of behavioural acuity. Its diagnostic power depends heavily on adequate, age-stratified, reference data, age-stratified empirical calibration with behavioural acuity, and interpretation in the light of other electrophysiological and clinical findings. Future developments could encompass faster, more objective and robust techniques such as real-time, adaptive control. REGISTRATION:International prospective register of systematic reviews PROSPERO (https://www.crd.york.ac.uk/PROSPERO/), registration number CRD42018085666

ISCEV extended protocol for VEP methods of estimation of visual acuity

The International Society for Clinical Electrophysiology of Vision (ISCEV) standard for visual evoked potentials (VEPs) describes a minimum procedure for clinical VEP testing and encourages more extensive testing. This ISCEV extended protocol is an extension to the VEP standard. It describes procedures for recording multiple VEPs to a range of sizes of pattern stimuli to establish the VEP spatial frequency limit (threshold) and for relating this limit to visual acuity

Treatment With Erythropoietin for Patients With Optic Neuritis: Long-term Follow-up.

BACKGROUND AND OBJECTIVE Erythropoietin (EPO) is a candidate neuroprotective drug. We assessed its long-term safety and efficacy as an adjunct to methylprednisolone in patients with optic neuritis and focused on conversions to multiple sclerosis (MS). METHODS The TONE trial randomized 108 patients with acute optic neuritis but without previously known MS to either 33,000 IU EPO or placebo in conjunction with 1,000 mg methylprednisolone daily for 3 days. After reaching the primary end point at 6 months, we conducted an open-label follow-up 2 years after randomization. RESULTS The follow-up was attended by 83 of 103 initially analyzed patients (81%). There were no previously unreported adverse events. The adjusted treatment difference of peripapillary retinal nerve fiber layer atrophy in relation to the fellow eye at baseline was 1.27 µm (95% CI -6.45 to 8.98, p = 0.74). The adjusted treatment difference in low-contrast letter acuity was 2.87 on the 2.5% Sloan chart score (95% CI -7.92 to 13.65). Vision-related quality of life was similar in both treatment arms (National Eye Institute Visual Functioning Questionnaire median score [IQR]: 94.0 [88.0 to 96.9] in the EPO and 93.4 [89.5 to 97.4] in the placebo group). The rate of multiple sclerosis-free survival was 38% in the placebo and 53% in the EPO group (hazard ratio: 1.67, 95% CI 0.96 to 2.88, p = 0.068). DISCUSSION In line with the results at 6 months, we found neither structural nor functional benefits in the visual system of patients with optic neuritis as a clinically isolated syndrome, 2 years after EPO administration. Although there were fewer early conversions to MS in the EPO group, the difference across the 2-year window was not statistically significant. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that for patients with acute optic neuritis, EPO as an adjunct to methylprednisolone is well tolerated and does not improve long-term visual outcomes. TRIAL REGISTRATION INFORMATION The trial was preregistered before commencement at clinicaltrials.gov (NCT01962571)

Lepton number violating interactions and their effects on neutrino oscillation experiments

Mixing between bosons that transform differently under the standard model gauge group, but identically under its unbroken subgroup, can induce interactions that violate the total lepton number. We discuss four-fermion operators that mediate lepton number violating neutrino interactions both in a model-independent framework and within supersymmetry (SUSY) without R-parity. The effective couplings of such operators are constrained by: i) the upper bounds on the relevant elementary couplings between the bosons and the fermions, ii) by the limit on universality violation in pion decays, iii) by the data on neutrinoless double beta decay and, iv) by loop-induced neutrino masses. We find that the present bounds imply that lepton number violating neutrino interactions are not relevant for the solar and atmospheric neutrino problems. Within SUSY without R-parity also the LSND anomaly cannot be explained by such interactions, but one cannot rule out an effect model-independently. Possible consequences for future terrestrial neutrino oscillation experiments and for neutrinos from a supernova are discussed.Comment: 28 pages, 2 figures, Late

Quantification of CH4 coal mining emissions in Upper Silesia by passive airborne remote sensing observations with the Methane Airborne MAP (MAMAP) instrument during the CO2 and Methane (CoMet) campaign

Methane (CH4) is the second most important anthropogenic greenhouse gas, whose atmospheric concentration is modulated by human-induced activities, and it has a larger global warming potential than carbon dioxide (CO2). Because of its short atmospheric lifetime relative to that of CO2, the reduction of the atmospheric abundance of CH4 is an attractive target for short-term climate mitigation strategies. However, reducing the atmospheric CH4 concentration requires a reduction of its emissions and, therefore, knowledge of its sources. For this reason, the CO2 and Methane (CoMet) campaign in May and June 2018 assessed emissions of one of the largest CH4 emission hot spots in Europe, the Upper Silesian Coal Basin (USCB) in southern Poland, using top-down approaches and inventory data. In this study, we will focus on CH4 column anomalies retrieved from spectral radiance observations, which were acquired by the 1D nadir-looking passive remote sensing Methane Airborne MAPper (MAMAP) instrument, using the weighting-function-modified differential optical absorption spectroscopy (WFM-DOAS) method. The column anomalies, combined with wind lidar measurements, are inverted to cross-sectional fluxes using a mass balance approach. With the help of these fluxes, reported emissions of small clusters of coal mine ventilation shafts are then assessed. The MAMAP CH4 column observations enable an accurate assignment of observed fluxes to small clusters of ventilation shafts. CH4 fluxes are estimated for four clusters with a total of 23 ventilation shafts, which are responsible for about 40 % of the total CH4 mining emissions in the target area. The observations were made during several overflights on different days. The final average CH4 fluxes for the single clusters (or sub-clusters) range from about 1 to 9 t CH4 h−1 at the time of the campaign. The fluxes observed at one cluster during different overflights vary by as much as 50 % of the average value. Associated errors (1σ) are usually between 15 % and 59 % of the average flux, depending mainly on the prevailing wind conditions, the number of flight tracks, and the magnitude of the flux itself. Comparison to known hourly emissions, where available, shows good agreement within the uncertainties. If only emissions reported annually are available for comparison with the observations, caution is advised due to possible fluctuations in emissions during a year or even within hours. To measure emissions even more precisely and to break them down further for allocation to individual shafts in a complex source region such as the USCB, imaging remote sensing instruments are recommended

Large-scale genome-wide association studies and meta-analyses of longitudinal change in adult lung function.

BACKGROUND: Genome-wide association studies (GWAS) have identified numerous loci influencing cross-sectional lung function, but less is known about genes influencing longitudinal change in lung function. METHODS: We performed GWAS of the rate of change in forced expiratory volume in the first second (FEV1) in 14 longitudinal, population-based cohort studies comprising 27,249 adults of European ancestry using linear mixed effects model and combined cohort-specific results using fixed effect meta-analysis to identify novel genetic loci associated with longitudinal change in lung function. Gene expression analyses were subsequently performed for identified genetic loci. As a secondary aim, we estimated the mean rate of decline in FEV1 by smoking pattern, irrespective of genotypes, across these 14 studies using meta-analysis. RESULTS: The overall meta-analysis produced suggestive evidence for association at the novel IL16/STARD5/TMC3 locus on chromosome 15 (P  =  5.71 × 10(-7)). In addition, meta-analysis using the five cohorts with ≥3 FEV1 measurements per participant identified the novel ME3 locus on chromosome 11 (P  =  2.18 × 10(-8)) at genome-wide significance. Neither locus was associated with FEV1 decline in two additional cohort studies. We confirmed gene expression of IL16, STARD5, and ME3 in multiple lung tissues. Publicly available microarray data confirmed differential expression of all three genes in lung samples from COPD patients compared with controls. Irrespective of genotypes, the combined estimate for FEV1 decline was 26.9, 29.2 and 35.7 mL/year in never, former, and persistent smokers, respectively. CONCLUSIONS: In this large-scale GWAS, we identified two novel genetic loci in association with the rate of change in FEV1 that harbor candidate genes with biologically plausible functional links to lung function

Design of production technology of specified component for conditions of workshop at IME FME Brno university of technology

Diplomová práce se zabývá návrhem a realizací technologie výroby součásti zadané firmou Frentech Aerospace s.r.o. pro podmínky dílny ÚST FSI VUT v Brně (laboratoře C2). Získaných poznatků je využito k návrhu inovované technologie výroby s využitím nástrojů firmy Pramet Tools, s.r.o. Technologie výroby součásti pro dílnu ÚST jsou zpracovány pro duralový materiál EN AW 6082. Součástí práce je technicko-ekonomické zhodnocení všech popsaných technologií výroby. Oba technologické postupy navržené pro podmínky laboratoře C2 jsou zhodnoceny společně a technologický postup firmy Frentech Aerospace s.r.o. je zhodnocen odděleně z důvodu zpracování technologie pro odlišný materiál polotovaru.Diploma thesis deals with design and implementation of manufacturing technology of a part which was given by company Frentech Aerospace s.r.o. Manufacturing technology is prepared for conditions of workshop of Department of Machining FME Brno UT (laboratory C2). Acquired knowledges are used for design of innovative manufacturing technology with cutting tools from company Pramet Tools, s.r.o. Manufacturing technologies of gained part are designed for alloy blank EN AW 6082. Technical-economical assessment of all manufacturing technologies is part of this thesis. Both of manufacturing technologies designed for laboratory C2 are assessed together and manufacturing technology given by company Frentech Aerospace s.r.o. is assessed alone due to using different blank material.

The preclinical pharmacology of the high affinity anti-IL-6R Nanobody (R) ALX-0061 supports its clinical development in rheumatoid arthritis

Introduction: The pleiotropic cytokine interleukin-6 (IL-6) plays an important role in the pathogenesis of different diseases, including rheumatoid arthritis (RA). ALX-0061 is a bispecific Nanobody (R) with a high affinity and potency for IL-6 receptor (IL-6R), combined with an extended half-life by targeting human serum albumin. We describe here the relevant aspects of its in vitro and in vivo pharmacology. Methods: ALX-0061 is composed of an affinity-matured IL-6R-targeting domain fused to an albumin-binding domain representing a minimized two-domain structure. A panel of different in vitro assays was used to characterize the biological activities of ALX-0061. The pharmacological properties of ALX-0061 were examined in cynomolgus monkeys, using plasma levels of total soluble (s)IL-6R as pharmacodynamic marker. Therapeutic effect was evaluated in a human IL-6-induced acute phase response model in the same species, and in a collagen-induced arthritis (CIA) model in rhesus monkeys, using tocilizumab as positive control. Results: ALX-0061 was designed to confer the desired pharmacological properties. A 200-fold increase of target affinity was obtained through affinity maturation of the parental domain. The high affinity for sIL-6R (0.19 pM) translated to a concentration-dependent and complete neutralization of sIL-6R in vitro. In cynomolgus monkeys, ALX-0061 showed a dose-dependent and complete inhibition of hIL-6-induced inflammatory parameters, including plasma levels of C-reactive protein (CRP), fibrinogen and platelets. An apparent plasma half-life of 6.6 days was observed after a single intravenous administration of 10 mg/kg ALX-0061 in cynomolgus monkeys, similar to the estimated expected half-life of serum albumin. ALX-0061 and tocilizumab demonstrated a marked decrease in serum CRP levels in a non-human primate CIA model. Clinical effect was confirmed in animals with active drug exposure throughout the study duration. Conclusions: ALX-0061 represents a minimized bispecific biotherapeutic of 26 kDa, nearly six times smaller than monoclonal antibodies. High in vitro affinity and potency was demonstrated. Albumin binding as a half-life extension technology resulted in describable and expected pharmacokinetics. Strong IL-6R engagement was shown to translate to in vivo effect in non-human primates, demonstrated via biomarker deregulation as well as clinical effect. Presented results on preclinical pharmacological properties of ALX-0061 are supportive of clinical development in RA